Australian Clinical Labs Ltd (ACL)

Currency in AUD
2.82
-0.02(-0.53%)
Delayed Data·

ACL Financial Summary

Key Ratios

P/E Ratio19.54
Price/Book3.54
Debt / Equity186.45%
Return on Equity18.56%
Dividend Yield4.42%
EBITDA76.31M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
* In Millions of AUD (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.15%
Dividend Yield
4.42%
Industry Median 3.07%
Annualised payout
0.13
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.74
(+32.58% Upside)

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
0.06 / --
Revenue / Forecast
369.17M / --
EPS Revisions
Last 90 days

FAQ

What were Australian Clinical Labs's earnings for the latest quarter?

The Australian Clinical Labs EPS (TTM) is 0.15. Australian Clinical Labs reported sales of 369.17, net income of 11.69, and EPS of 0.06 for the latest quarter.

What was Australian Clinical Labs's net income for the latest quarter?

Australian Clinical Labs's net income for the latest quarter was 11.69.

How did Australian Clinical Labs's performance compare year-over-year in the latest quarter?

The company's revenue moved from 359.10 in the previous quarter to 369.17 in the latest quarter, and net income moved from 18.98 to 11.69 compared to the previous quarter.

What is Australian Clinical Labs's net profit margin on a TTM basis?

Australian Clinical Labs's trailing twelve months (TTM) net profit margin is 3.44%.

How does Australian Clinical Labs's debt to equity ratio compare to industry standards?

Australian Clinical Labs's total debt-to-equity ratio is 186.45%.

What is Australian Clinical Labs's return on investment on a TTM basis?

Australian Clinical Labs's trailing twelve months (TTM) return on investment (ROI) is 18.56%.

Did Australian Clinical Labs gain or lose cash last quarter?

In the latest quarter, Australian Clinical Labs's net change in cash was -5.32 million.

What were Australian Clinical Labs's total assets and liabilities in the latest quarter?

As of the latest quarter, Australian Clinical Labs reported total assets of 585.09 million and total liabilities of 207.92 million.

How has Australian Clinical Labs's total revenue grown this year?

Australian Clinical Labs's total revenue was 359.10 in the previous quarter and 369.17 in the latest quarter.

What is Australian Clinical Labs's gross margin on a TTM basis?

Australian Clinical Labs's trailing twelve months (TTM) gross margin is 36.49%.

What was Australian Clinical Labs's revenue per share for the latest quarter?

Australian Clinical Labs's revenue per share for the latest quarter was 30.16.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.